Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences

Rhea-AI Summary

Allogene Therapeutics, Inc. (Nasdaq: ALLO) has announced its participation in four upcoming investor conferences. These events include:

• Canaccord Genuity - CG Horizons in Oncology Virtual on April 20, 2023, at 8:00 AM PT
• BofA Securities 2023 Health Care Conference on May 10, 2023, at 4:20 PM PT
• The JMP Securities Life Sciences Conference on May 15, 2023, at 8:30 AM PT
• 2023 RBC Capital Markets Global Healthcare Conference on May 16, 2023, at 1:35 PM PT

Webcasts of these events will be available on the company’s website under the Investors tab. Allogene Therapeutics focuses on developing allogeneic CAR T products aimed at improving cancer treatment, striving to provide 'off-the-shelf' therapies for patients.

SOUTH SAN FRANCISCO, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in four upcoming investor conferences.

Canaccord Genuity - CG Horizons in Oncology Virtual
Thursday, April 20, 2023
8:00AM PT/11:00AM ET

BofA Securities 2023 Health Care Conference
Wednesday, May 10, 2023
4:20PM PT/7:20PM ET

The JMP Securities Life Sciences Conference
Monday, May 15, 2023
8:30AM PT/11:30AM ET

2023 RBC Capital Markets Global Healthcare Conference
Tuesday, May 16, 2023
1:35PM PT/4:35PM ET

Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T products for cancer and the potential benefits of AlloCAR T. Various factors may cause material differences between Allogene’s expectations and actual results, including, risks and uncertainties related to: our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factors” heading of its Form 10-K for the year ended December 31, 2022. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com

FAQ

When is Allogene Therapeutics participating in investor conferences in 2023?

Allogene Therapeutics will participate in investor conferences on April 20, May 10, May 15, and May 16, 2023.

What type of conference will Allogene Therapeutics attend on April 20, 2023?

On April 20, 2023, Allogene Therapeutics will attend the Canaccord Genuity - CG Horizons in Oncology Virtual conference.

Where can I find webcasts of Allogene Therapeutics' investor conferences?

Webcasts of Allogene Therapeutics' investor conferences will be available on their website under the Investors tab.

What is Allogene Therapeutics known for?

Allogene Therapeutics is known for developing allogeneic CAR T products for cancer treatment.

What is the goal of Allogene Therapeutics in their CAR T product development?

The goal of Allogene Therapeutics is to deliver readily available 'off-the-shelf' cell therapies to patients.